Bill Sweeney’s RFU fate to be decided after Six Nations following U-turn
Aston Villa v West Ham United: FA Cup third round – live
Novak Djokovic’s claim he ate ‘poisoned’ food in 2022 Melbourne hotel detention ‘possible but very unlikely’, experts say
Starmer’s top aide made low-key Brussels trip as No 10’s EU reset efforts continue
World’s ugliest lawn winner says she leaves watering to Mother Nature
MHRA authorises uses of Casgevy as a potential cure for sickle cell disease and beta thalassemia
Britain’s drugs regulator has approved a groundbreaking treatment for two painful and debilitating lifelong blood disorders, which works by “editing” the gene that causes them.
The Medicines and Healthcare products Regulatory Agency (MHRA) has given the green light for Casgevy to be used to treat sickle cell disease and beta thalassemia.
More Stories
Male mosquitoes to be genetically engineered to poison females with semen in Australian research
Bizarre Australian mole even more unusual than first thought, new research reveals
Breakthrough drugs herald ‘new era’ in battle against dementia, experts predict